Thin
1 / 1
This is the main indication for which Semax has been approved in Russia. It is used in the acute and recovery phases to limit the infarct area, protect dying neurons, and promote functional recovery.
Used to treat vascular and post-traumatic cognitive impairment, it can improve memory, attention and psychological performance.
as an adjunct therapy, especially effective for depressive states associated with burnout and cognitive decline.
Its potential for use in Alzheimer's and Parkinson's diseases is being investigated, primarily based on its neurotrophic and protective effects.
Used to treat optic nerve damage and atrophy caused by diseases such as glaucoma.
In some regions (for non-medical purposes), it is used as a "nootropic" to enhance learning, memory, and mental concentration under stress.
The greatest potential lies in its application to a wider range of neurodegenerative diseases. Preclinical and clinical studies are underway for Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
Semax may be used in combination with other neuroprotective agents or rehabilitation therapies to produce a synergistic effect and enhance treatment outcomes.
Researchers are developing analogues that are more potent and have a longer duration of action than Semax (e.g., Selank is used for anxiety, and Adamamax is a more stable version of Semax).
Currently, Semax is mainly used in Russia and some Eastern European countries. If it can pass rigorous clinical trials and obtain regulatory approval (such as FDA approval) in developed Western countries (such as the United States and the European Union), it will greatly promote its global application.
Although there has been extensive research in the former Soviet Union, its efficacy and safety still need to be confirmed through large-scale clinical trials that meet international standards (such as randomized, double-blind, placebo-controlled trials) to meet the requirements of regulatory agencies such as the FDA and EMA.
Although there is a basic understanding of its mechanism, more precise molecular pathways still need to be explored.
Globally, Semax has far lower awareness than traditional neurological drugs, requiring extensive market education and commercial promotion.
Semax is a synthetic peptide drug derived from a fragment of adrenocorticotropic hormone (ACTH). It was initially developed in Russia in the 1980s by the Institute of Molecular Genetics of the Russian Academy of Sciences.
Unlike its parent hormone ACTH, which primarily affects the adrenal glands, Semax removes hormonal activity but retains and significantly enhances its potent effects on the central nervous system.
Semax shows great potential in neuroscience and psychiatry. Its main approved indication in Russia is for ischemic stroke. It is also used for cognitive impairment, anxiety, depressive disorders, optic neuropathy, and is being investigated for neurodegenerative diseases.
In some regions, Semax is used for non-medical purposes as a "nootropic" or cognitive enhancer to improve learning, memory, and mental concentration under stress.
The future prospects for Semax include expanding indications to treat Alzheimer's and Parkinson's diseases, using it in combination therapies, developing more potent novel analogues like Adamamax, and expanding into the global market.
Semax faces challenges such as the need for rigorous clinical validation to meet international standards (like FDA and EMA requirements), the need for precise elucidation of its mechanism of action, and low global commercial awareness.
